Drug makers’ downsizing plan hits snag

Published: 2012-05-24 06:58:00

Updated: 2012-05-24 06:58:00

The domestic drug industry has hit a snag with its plan to push employees to opt for early retirement plans amid growing worries over the lackluster earnings outlook, with most pharmaceutical firms reluctant to reduce their workforces on concerns over union’s strong resistance and disclosure of i...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK